-
ABOUT USSSY Group Limited is a large high-tech pharmaceutical enterprise with coordinated development of R&D and industrialization in multiple fields such as new drugs, generic drugs, characteristic APIs
-
INNOVATIONSSY Group Limited has built a relatively perfect scientific research and innovation system with the development mode of “production, learning, research, and application” of multi-disciplinary integration and multi-directional combination.
-
RECRUITIt has established high-level innovation platforms such as engineering laboratory and technology research center jointly with Chinese Academy of Sciences, and now has nearly 400 high-level talents in drug research, analysis and clinical research.
-
SUBSIDIARIESThe company has a diversified business development pattern of R&D, production and export of new drugs, generic drugs, characteristic APIs, advanced finished pharmaceutical products, biological preparations and pharmaceutical packaging materials.
-
CONTACTWe will continue to strengthen innovation-driven development, will vigorously encourage the integration of production and research, strengthen and improve the five domains: new drugs, biological drugs, traditional Chinese medicine, generic drugs and APIs
Shijiazhuang Sihua Pharmaceutical Group Makes a Striking Appearance at the 89th API China Exhibition
Category:
发布时间：2023-10-19
【概要描述】
On October 18, the 89th China International API, Intermediates, Packaging and Equipment Exhibition (API China) grandly opened at the Nanjing International Expo Center. In Hall 8, the eye-catching blue-and-white custom-designed booth of Shijiazhuang Sihua Pharmaceutical Group—jointly presented by Guangxiang Pharmaceutical, Guolong Pharmaceutical, and Bosheng Medical Devices—stood out for its innovative design and sophisticated aesthetic, quickly becoming a social media sensation at the event.
On October 18, the 89th China International API, Intermediates, Packaging and Equipment Exhibition (API China) grandly opened at the Nanjing International Expo Center. In Hall 8, the eye-catching blue-and-white custom-designed booth of Shijiazhuang Sihua Pharmaceutical Group—jointly presented by Guangxiang Pharmaceutical, Guolong Pharmaceutical, and Bosheng Medical Devices—stood out for its innovative design and sophisticated aesthetic, quickly becoming a social media sensation at the show.
Upon entering the Group’s exhibition booth, a neatly arranged row of exquisitely designed lightbox posters showcasing the Group’s signature API products and pharmaceutical packaging materials immediately caught the attention of numerous visitors, who stopped to inquire. Several customers eagerly made their way to the booth’s consultation area, where the Group’s domestic and international API sales teams and pharmaceutical packaging marketing staff enthusiastically briefed both new and existing clients on the Group’s innovative development achievements and the competitive advantages of its bulk APIs and pharmaceutical packaging materials. In turn, these clients expressed their strong interest in establishing and strengthening cooperation with the Group.
In recent years, the Group has strategically positioned itself at the upstream end of the value chain and implemented an integrated “API–formulation” development strategy, thereby establishing a new industrial landscape characterized by comprehensive and well-coordinated supply chains spanning specialty APIs, generic drugs, innovative medicines, and pharmaceutical packaging materials. Its flagship products—such as caffeine, azithromycin, metronidazole, nifedipine, moxifloxacin hydrochloride, bromhexine hydrochloride, and tinidazole—which are renowned for their high quality and strong market reputation, have won widespread acclaim from customers and enjoy robust demand in international markets, with sales spanning dozens of countries worldwide. As a result, the Group is accelerating its ascent to the ranks of China’s leading API manufacturers. Meanwhile, nearly 50 specialty APIs—including epalrestat, pitavastatin calcium, rosuvastatin calcium, lacosamide, pentoxifylline, levornidazole, and ornidazole—are steadily demonstrating their competitive advantages in the market, serving as key suppliers to numerous formulation manufacturers and injecting fresh momentum into the sustained growth of the Group’s API business segment, while also infusing vibrant vitality into the deepening of the Group’s structural adjustments. In addition, the Group’s pharmaceutical packaging products—such as non-PVC infusion films, coated septa, film-coated rubber stoppers, and cleanroom-free halogenated butyl rubber stoppers—have become well-known, industry-leading brands.
Su Xuejun, Chairman of the Group, stated that the Group will focus on product upgrading and international expansion, continuously prioritizing the development of specialty APIs with strong market value. With a customer-centric approach, the Group will remain attentive to customer needs, strive to deliver higher-quality services and greater product value, and achieve mutually beneficial growth.
According to reports, this exhibition has brought together more than 1,200 companies nationwide specializing in pharmaceutical APIs, pharmaceutical excipients, pharmaceutical packaging, and pharmaceutical equipment, comprehensively showcasing the latest products, technologies, and end-to-end solutions for drug manufacturing and R&D. The event also promotes advanced pharmaceutical principles and actively fosters exchange and collaboration across the entire R&D and production lifecycle and the full industry value chain among enterprises and within the industry.
Keywords:
Recommended News
Share to
SERVICE HOTLINE
Address: Shimen Building, No. 8 Xingye Street, Shijiazhuang Economic and Technological Development Zone
Tel.: +86-311-67167130
Email: office@sjzsiyao.com
Mobile site
E code
Non-Commercial (Filing) – 2025-0091